Smartphone Measured Eye-Based Digital Biomarkers for Drug Use Detection

Projektinformationen

PrevictDrugs

ID Finanzhilfevereinbarung: 876553

DOI

10.3030/876553

Projekt abgeschlossen

EK-Unterschriftsdatum 2 August 2019

Startdatum 1 September 2019

Enddatum 29 Februar 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

KONTIGO CARE AB
Sweden

Periodic Reporting for period 1 - PrevictDrugs (Smartphone Measured Eye-Based Digital Biomarkers for Drug Use Detection)

Berichtszeitraum: 2019-09-01 bis 2020-02-29

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Globally, 250 million have used drugs, 27 million suffer from problem drug use and 187,100 deaths occurred as a direct consequence of drug use. Thus, drug abuse needs to be controlled and monitored. Addiction treatments in the EU focus on out-patient relapse prevention strategies due to the limited healthcare resources at hand. However, for these approaches to become effective, daily, low-cost monitoring of sobriety and risk assessment of relapse are required. Current reaction times are too slow as caregivers lack tools to identify relapses in real-time. Consequently, there is an urgent need to change conservative approaches and improve treatment outcomes for the growing number of patients. The reach and speed of web and app applications are tremendous and timing and readiness for Europa’s Health care are optimal. This is the gap Kontigo Care aims to address through the SME Instrument project.

The overall objective of this project was to develop and optimize a business plan that will guide the development and commercialization of Kontigo Care’s Previct Drugs - a robust, app-based, eHealth-platform for continuous self-monitoring of drug use.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

Kontigo Care performed the feasibility study which will guide the development, clinical validation and commercialisation of Previct Drugs. The study has provided a valuable understanding of the market, targeted users, competitive landscape, and regulatory pathways. The clinical evaluation plan has also been developed as a part of the project.

The feasibility study has confirmed a significant business opportunity within the global drug use monitoring market.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

This feasibility study has further confirmed the innovative character of Kontigo Care’s approach. Our Previct Drugs medical device will constitute an add-on to Kontigo Care’s current eHealth offer developed for the management of other addictive disorders (alcohol abuse and hazard gambling). On the patient’s side, the data will be collected with a smartphone app capable of measuring eye parameters – pupillometry-based method for monitoring the use of illicit drugs.

We strive to develop our prototype further and validate the potential for a medical device that will enable early therapeutic interventions, daily home-based therapeutic interventions and appropriate distribution of healthcare resources. Drug abuse is a serious global health problem and Kontigo Care is convinced its innovative approach will have a significant impact on the health-economic burden of drug abuse in Europe and worldwide.

Kontigo Care - mission statement